Perflubron

Perflubron
Clinical data
ATC code	V08CX01 (WHO) ;
Identifiers
	IUPAC name 1-Bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane;
CAS Number	423-55-2;
PubChem CID	9873;
ChemSpider	9489;
UNII	Q1D0Q7R4D9;
ChEMBL	ChEMBL1200866;
CompTox Dashboard (EPA)	DTXSID5046560 ;
ECHA InfoCard	100.006.391
Chemical and physical data
Formula	C8BrF17
Molar mass	498.965 g·mol−1
3D model (JSmol)	Interactive image;
Density	1.93 g/cm3
Melting point	6 °C (43 °F)
Boiling point	142 °C (288 °F)
	SMILES FC(F)(C(F)(F)C(Br)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F;
	InChI InChI=1S/C8BrF17/c9-7(22,23)5(18,19)3(14,15)1(10,11)2(12,13)4(16,17)6(20,21)8(24,25)26; Key:WTWWXOGTJWMJHI-UHFFFAOYSA-N;

Perflubron (INN/USAN, or perfluorooctyl bromide; brand name Imagent) is a contrast medium for magnetic resonance imaging, computer tomography and sonography.^[1] It was approved for this use in the United States by the Food and Drug Administration in 1993.^[2]

Experimental research

Perflubron has also been tested experimentally for use in liquid breathing in premature infants with respiratory distress.^[3]^[4]

This molecular model of Perflubron is color-coded by electron density to illustrate the positive polarisation of the large bromine atom by the inductively electron-withdrawing perfluorooctyl chain.

References

↑ Mattrey RF (February 1989). "Perfluorooctylbromide: a new contrast agent for CT, sonography, and MR imaging". AJR. American Journal of Roentgenology. 152 (2): 247–52. doi:10.2214/ajr.152.2.247. PMID 2643258.
↑ FDA Approved Drug Products
↑ Wolfson MR, Kechner NE, Roache RF, DeChadarevian JP, Friss HE, Rubenstein SD, Shaffer TH (February 1998). "Perfluorochemical rescue after surfactant treatment: effect of perflubron dose and ventilatory frequency". Journal of Applied Physiology. 84 (2): 624–40. doi:10.1152/jappl.1998.84.2.624. PMID 9475875.
↑ Leach CL, Greenspan JS, Rubenstein SD, Shaffer TH, Wolfson MR, Jackson JC, et al. (September 1996). "Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group". The New England Journal of Medicine. 335 (11): 761–7. doi:10.1056/NEJM199609123351101. PMID 8778584.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Mattrey RF (February 1989). "Perfluorooctylbromide: a new contrast agent for CT, sonography, and MR imaging". AJR. American Journal of Roentgenology. 152 (2): 247–52. doi:10.2214/ajr.152.2.247. PMID 2643258.

[2] FDA Approved Drug Products

[3] Wolfson MR, Kechner NE, Roache RF, DeChadarevian JP, Friss HE, Rubenstein SD, Shaffer TH (February 1998). "Perfluorochemical rescue after surfactant treatment: effect of perflubron dose and ventilatory frequency". Journal of Applied Physiology. 84 (2): 624–40. doi:10.1152/jappl.1998.84.2.624. PMID 9475875.

[4] Leach CL, Greenspan JS, Rubenstein SD, Shaffer TH, Wolfson MR, Jackson JC, et al. (September 1996). "Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group". The New England Journal of Medicine. 335 (11): 761–7. doi:10.1056/NEJM199609123351101. PMID 8778584.

[1]

[2]

[3]

[4]